Clinical trial
Preventive IVIG Therapy for Congenital Heart Block
NCT00460928 · NYU Langone Health, Other · Completed
Key facts
| NCT number | NCT00460928 |
|---|---|
| Title | Preventive IVIG Therapy for Congenital Heart Block |
| Official title | Preventive IVIG Therapy for Congenital Heart Block (The PITCH Study) |
| Acronym | PITCH |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | Lupus Research Alliance |
| Status | Completed |
| Phase | Early Phase 1 |
| Study type | Interventional |
| Conditions | Congenital Heart Block, Neonatal Lupus, Autoantibody-associated Heart Block |
| Intervention type | Drug |
| Interventions | intravenous immune globulin (IVIG) |
| Enrollment | 20 |
| Start date | Apr 1, 2007 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Apr 17, 2007 |
| Last update posted | Sep 30, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: